Doxofylline: A New Generation Xanthine Bronchodilator Devoid of Major Cardiovascular Adverse Effects

References

• Manning, H. L. (2000). Bronchodilator therapy in chronic obstructive pulmonary disease. Curr. Opin. Med., 6, 99–103.
   PubMedGoogle Scholar
• Barnes, P. J. and Pauwels, R. A. (1994). Theophylline in the management of asthma: time for reappraisal? Eur. Respir. J., 7, 579–591.
   PubMed Web of Science ®Google Scholar
• McFadden, E. R., Jr and Braunwald, E. (1992). Cor pulmonale. In: Braunwald, E. (Ed). Heart Disease. WB Saunders, Philadelphia, pp. 1581–1601.
   Google Scholar
• Bittar, G. and Friedman, H. S. (1991). Arrhythmogenicity of theophylline: a multivariate analysis of clinical determinants. Chest, 99, 1415–1420.
   PubMed Web of Science ®Google Scholar
• Holford, F. D. and Mithoefer, J. C. (1973). Cardiac arrhythmias in hospitalized patients with chronic obstructive pulmonary disease. Am. Rev. Resp. Dis., 108, 879–885.
   PubMed Web of Science ®Google Scholar
• Buxton, A. E., Marchlinsky, F., Doherty, J. et al. (1984). Repetitive, monomorphic ventricular tachycardia: clinical and electrophysiological characteristics in patients with or without organic heart disease. Am. J. Cardiol., 54, 997–1002.
   PubMed Web of Science ®Google Scholar
• Higgins, R. M., Cookson, W. O. C. M., Lane, D. J., John, S. M. and MacCarthy, S. T. (1987). Cardiac arrhythmias caused by nebulized beta-agonist therapy. Lancet, 11, 863–864.
   Google Scholar
• Lofdhal, C. Q. and Svedmyr, N. (1991). Beta-agonists. Friends or foes? Eur. Respir. J., 4, 1161–1165.
   Google Scholar
• Cazzola, M., Imperatore, R, Salzillo, A., Di Perna, R, Calderaro, R, Imperatore, A., Matera, M. G. (1998). Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest, 114, 411–415.
   PubMed Web of Science ®Google Scholar
• Zimet, I. (1994). Infrequent cardiac deaths occur in bronchial asthma. Chest, 101, 1703–1705.
   Web of Science ®Google Scholar
• Hall, J. P., Woodhead, M. A. and Johnston, I. D. (1994). Effect of high-dose salbutamol on cardiac rhythm in severe chronic airflow obstruction: a controlled study. Respiration, 61, 214–218.
   PubMed Web of Science ®Google Scholar
• Castle, W., Fuller, R., Hall, J. and Palmer, J. (1993). Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. Br. Med. J., 306, 1034–1037.
   PubMed Web of Science ®Google Scholar
• Spitzer, W. O., Suissa, S., Ernst, P. et al. (1992). The use of beta-agonists and the risk of death or near death from asthma. N. Engl. J. Med., 326, 501–506.
   PubMed Web of Science ®Google Scholar
• Robin, E. G. and McCauley, R. (1992). Sudden cardiac death in bronchial asthma, and inhaled I3-adrenergic agents. Chest, 101, 1699–1702.
   PubMed Web of Science ®Google Scholar
• Suissa, S., Hemmelgarn, B., Blais, L. and Ernst, P. (1996). Bronchodilators and acute cardiac death. Am. J. Respir. Crit. Care Med., 154, 1598–1602.
   PubMed Web of Science ®Google Scholar
• Gillum, R., Makuc, D. and Feldman, J. (1985). Pulse rate, coronary heart disease and death: the NHANES I epidemilogical follow-up study. Am. Heart J., 109, 876–885.
   PubMedGoogle Scholar
• Kannel, W. B., Kannel, C., Paffenbarger, R. S., Jr and Cupples, L. A. (1987). Heart rate and cardiovascular mortality: The Framingham Study. Am. Heart J., 113, 1489–1494.
   PubMed Web of Science ®Google Scholar
• Palatini, P., Casiglia, S., Julius, S. and Pessina, A. C. (1999). Heart rate, a risk factor for cardiovascular mortality in elderly men. Arch. Intern. Med., 159, 585–592.
   PubMed Web of Science ®Google Scholar
• St John Sutton, M., Pfeffer, M. A., Moye, L. et al. (1997). Cardiovascular death and left ventricular remodelling two years after myocardial infarction. Baseline predictors and impact of long term use of captopril: information from the survival and ventricular enlargement (SAVE) trial. Circulation, 96, 324–329.
   Google Scholar
• Shizukuda, Y., Buttrick, P. M., Geenen, D. L., Borczuk, A. C., Kitsis, R. N. and Sonnemblick, E. H. (1998). Beta-adrenergic stimulation causes cardiocyte apoptosis: influence of tachycardia and hypertrophy. Am. J. Physiol., 275, H961–H968.
   PubMed Web of Science ®Google Scholar
• Kjekshus, J. (1985). Beta-blockers: heart rate reduction as a mechanism of benefit. Eur. Heart J., 6, 29–30.
   Web of Science ®Google Scholar
• Corea, L., Bentivoglio, M., Verdecchia, P. et al. (1984). Noninvasive assessment of chronotropic and inotropic response to preferential 131 and 132 adrenoreceptor stimulation. Clin. Pharmacol. Ther, 35, 776–781.
   PubMed Web of Science ®Google Scholar
• Billman, G. E., Castillo, L. C., Hensley, J., Hohl, C. M. and Altschuld, R. A. (1997). Beta2-adrenergic receptor antagonists protect against ventricular fibrillation: in vivo and in vitro evidence of enhanced sensitivity to beta2-adrenergic stimulation in animals susceptible to sudden death. Circulation, 96, 1914–1922.
   PubMed Web of Science ®Google Scholar
• Bristow, M. R., Ginsburg, R., Minobe, W. et al. (1982). Decreased catecholamine sensitivity and beta-adrenergic receptor density in failing human hearts. N. Engl. J. Med., 307, 205–211.
   PubMed Web of Science ®Google Scholar
• A randomized trial of propanolol in patients with acute myocardial infarction. I. Mortality results. JAMA, 247, 1707–1714.
   Google Scholar
• Gudersen, T. (1983). Influence of heart size on mortality and reinfarction in patients treated with timolol after myocardial infarction. Br. Heart J., 50, 135–139.
   PubMedGoogle Scholar
• Packer, M., Bristow, M. R., Cohn, J. N. et al. (1996). The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N. Engl. J. Med., 334, 1349–1355.
   PubMed Web of Science ®Google Scholar
• Yusuf, S., Peto, R., Lewis, J., Collins, R. and Sleight, P. (1985). Beta-blockade during and after myocardial infarction: an overview of the randomised trials. Prog. Cardiovasc. Dis., 27, 335–371.
   PubMed Web of Science ®Google Scholar
• Hampton, J. R. (1996). Beta-blockers in heart failure: the evidence from clinical trials. Eur Heart J., 17 (Suppl B), 17–20.
   PubMed Web of Science ®Google Scholar
• Kurachi, Y. (1995). Adenosine and adenine nucleotide action on cardiac cellular excitation. In: Sperelakis, N. (Ed), Physiology and Pathophysiology of the Heart. Kluwer, Dordrecht, 3rd edn, pp. 789–800.
   Google Scholar
• Ogilvie, R. I., Fernandez, P. G. and Winsberg, F. (1977). Cardiovascular response to increasing theophylline concentrations. Eur. J. Clin. Pharmacol., 12, 409–414.
   PubMed Web of Science ®Google Scholar
• Varriale, P. and Ramaprasad, S. (1993). Aminophylline induced atrial fibrillation. Pacing Clin. Electrophysiol., 16, 1953–1955.
   PubMed Web of Science ®Google Scholar
• Chazan, R., Karwat, K., Tyminska, K. and Tadeusiak, W. (1995). Cardiac arrhythmias as a result of intravenous infusion of theophylline in patients with airway obstruction. Int. J. Clin. Pharmacol. Ther, 33, 170–175.
   PubMed Web of Science ®Google Scholar
• Hendeles, L., Bighley, L. and Richardson, R. H. (1977). toxicity form IV aminophylline infusion in critical ill patients. Drug Intell. Clin. Pharmacol., 1, 13–18.
   Google Scholar
• Marchlinsky, FE. and Miller, J. M. (1985). Atrial arrhythmias exacerbated by theophylline. Response to verapamil and evidence for triggered activity in man. Chest, 88, 931–934.
   PubMed Web of Science ®Google Scholar
• Biaggioni, I., Paul, S., Puckett, A. and Arzubiag, A. C. (1991). Caffeine and theophylline as adenosine receptor antagonists in humans. J. Pharmacol. Expl. Ther, 258, 89–97.
   Google Scholar
• Peerson, C. G. A. (1982). Universal adenosine receptor antagonism is neither necessary nor desirable with xanthine antiasthmatic. Med. Hypoth., 8, 515–526.
   PubMed Web of Science ®Google Scholar
• Peerson, C. G. A. (1985). The profile of action of enprophylline, or why adenosine antagonism seems less desirable with xanthine antiasthmatic. In: Morley, J. and Rainsford, K. D. (Eds), Pharmacology of Asthma. Birkhauser-Verlag, Basel, pp. 115–129.
   Google Scholar
• Benditt, D. G., Benson, D. W., Kreitt, J. et al. (1983). Electrophysiologic effects of theophylline in young patients with recurrent symptomatic bradyarrhythmias. Am. J. Cardiol., 52, 1223–1229.
   PubMed Web of Science ®Google Scholar
• Franzone, J. S., Cirillo, R. and Barone, D. (1988). Doxofylline and theophylline are xanthines with partly different mechanisms of action in animals. Drug Explt. Clin. Res., 14, 479–489.
   PubMedGoogle Scholar
• Cirillo, R., Barone, D. and Franzone, J. S. (1988). Doxofylline, an antiasthmatic drug lacking affinity for adenosine receptors. Arch. Int. Pharmacodyn., 295, 221–237.
   PubMedGoogle Scholar
• Cirillo, R., Grossi, E. and Franzone, J. S. (1989). Doxofylline, an adenosine non-blocking xanthine, does not induce cardiostimulants effects. Res. Com. Chem. Path. Pharmacol., 65, 21–34.
   PubMedGoogle Scholar
• Evoniuk, G., Jacobson, K. A., Shamin, M. T. and Wurtman, R. J. (1987). Al- and A2 - selective adenosine antagonists: in vivo characterisation of cardiovascular effects. J. Pharmacol. Exp. Ther, 242, 882–887.
   PubMed Web of Science ®Google Scholar
• Bagnato, G. F., Allegra, A., De Leo, A. et al. (1989). Effetti sul sistema cardio-respiratorio indotti dalla doxofillina. Eur. Rev. Pharmacol. Sci., 11, 29–35.
   Google Scholar
• Dini, F. L. (1991). Chronotropic and arrhythmogenic effects of two methyl-xanthine bronchodilators, doxofylline and theophylline, evaluated by Hotter monitoring. Cum Ther. Res., 49, 978–984.
   Web of Science ®Google Scholar
• Cipri, A., Pozzar, F. and Dini, F. L. (1992). Alterazioni del ritmo cardiaco in pazienti con broncopneumopatia cronica ostruttiva. Minerva Cardioangiol., 40, 31–39.
   PubMedGoogle Scholar
• Giorgi, M., Sestini, P., Bracciale, P. M., Rosi, P., Micheletti, C., Rottoli, P. and Vagliasindi, M. (1993). Treatment with xanthine derivative, doxofylline, in patients intollerant to theophylline. Eur. Respir. J., 6 (Suppl 17), Abstract No. 417.
   Google Scholar
• Checchini, M., Magni, M., Scaglione, M., Franzini, C., Vaccarella, A. and Omboni, E. (1997). Studio clinico controllato doxofillina versus aminofillina nel trattamento delle sindromi da insufficienza acuta cardio - respiratoria. Minerva Cardioangiol., 45, 185–190.
   PubMedGoogle Scholar
• Melillo, G., Balzano, G., Jodice, F. et al. (1989). Treatment of reversible chronic airways obstruction with doxofylline compared with slow-release theophylline: a double-blind, randomized, multicentre trial. Int. J. Clin. Pharm. Res., 9, 397–405.
   PubMedGoogle Scholar
• Dini, F. L. on behalf of the Doxofylline in Reversible Asthma Study Group (2000). Doxofylline compared to theophylline in chronic reversible asthma. A double-blind placebo-controlled study. J. Cl. Pharmacol., 40, Abstract 1051.
   Google Scholar
• Villani, F., De Maria, P., Ronchi, E. and Galimberti, M. (1997). Oral doxofylline in patients with chronic obstructive pulmonary disease. Int. J. Cl. Pharm. Ther, 35, 107–111.
   PubMed Web of Science ®Google Scholar
• Faggiano, P., Lombardi, C., Sorgato, A., Ghizzoni, G., Spedini, C. and Rusconi, C. (1993). Pulmonary function tests in patients with congestive heart failure. Cardiology, 83, 30–35.
   PubMed Web of Science ®Google Scholar
• Mancini, D. M. (1995). Pulmonary factors limiting exercise capacity in patients with heart failure. Prog. Cardiovasc. Dis., 37, 347–370.
   PubMed Web of Science ®Google Scholar
• Rolla, G., Bucca, C., Brussino, L., Bergerone, S. and Pecchio, F. (1993). Atrial natriuretic peptide and bronchial hyperresponsiveness in patients with mitral stenosis. Respiration, 60, 74–77.
   PubMed Web of Science ®Google Scholar
• Uren, N., Davies, S., Jordan, S. et al. (1993). Inhaled bronchodilators increase maximum oxygen consumption in chronic left ventricular failure. Eur. Heart J., 14, 744–750.
   PubMed Web of Science ®Google Scholar
• Mirabelli, S. and Dini, F. L. (2000). Pulmonary function tests in patients with chronic heart failure and chronic airway obstruction. Effects of doxofylline. Rev. Colomb. Neumolog ., 12, S22.
   Google Scholar
• Dini, F. L. (1995). Oral administered methylxanthines improve gas exchange and exercise tolerance in patients with chronic hypoxaemic heart failure. Eur. Heart J., 16 (Suppl), Abstract 151.
   PubMedGoogle Scholar
• Dini, F. L., Pasini, G., Cortellini, G. et al. (1993). Methylxanthine drug therapy in chronic heart failure associated with hypoxaemia: double-blind placebo controlled clinical trial of doxofylline versus theophylline and bamifylline. Int. J. Clin. Pharm. Res., 13, 305–316.
   PubMedGoogle Scholar